OBJECTIVE: To provide detailed information about costs of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) treatment stages and to estimate the cost per IVF and ICSI treatment cycle and ongoing pregnancy. DESIGN: Descriptive micro-costing study. SETTING: Four Dutch IVF centers. PATIENT(S): Women undergoing their first treatment cycle with IVF or ICSI. INTERVENTION(S): IVF or ICSI. MAIN OUTCOME MEASURE(S): Costs per treatment stage, per cycle started, and for ongoing pregnancy. RESULT(S): Average costs of IVF and ICSI hormonal stimulation were euro 1630 and euro 1585; the costs of oocyte retrieval were euro 500 and euro 725, respectively. The cost of embryo transfer was euro 185. Costs per IVF and ICSI cycle started were euro 2381 and euro 2578, respectively. Costs per ongoing pregnancy were euro 10,482 and euro 10,036, respectively. CONCLUSION(S): Hormonal stimulation covered the main part of the costs per cycle (on average 68% and 61% for IVF and ICSI, respectively) due to the relatively high cost of medication. The costs of medication increased with increasing age of the women, irrespective of the type of treatment (IVF or ICSI). Fertilization costs (IVF laboratory) constituted 12% and 20% of the total costs of IVF and ICSI. The total cost per ICSI cycle was 8.3% higher than IVF.
OBJECTIVE: To provide detailed information about costs of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) treatment stages and to estimate the cost per IVF and ICSI treatment cycle and ongoing pregnancy. DESIGN: Descriptive micro-costing study. SETTING: Four Dutch IVF centers. PATIENT(S): Women undergoing their first treatment cycle with IVF or ICSI. INTERVENTION(S): IVF or ICSI. MAIN OUTCOME MEASURE(S): Costs per treatment stage, per cycle started, and for ongoing pregnancy. RESULT(S): Average costs of IVF and ICSI hormonal stimulation were euro 1630 and euro 1585; the costs of oocyte retrieval were euro 500 and euro 725, respectively. The cost of embryo transfer was euro 185. Costs per IVF and ICSI cycle started were euro 2381 and euro 2578, respectively. Costs per ongoing pregnancy were euro 10,482 and euro 10,036, respectively. CONCLUSION(S): Hormonal stimulation covered the main part of the costs per cycle (on average 68% and 61% for IVF and ICSI, respectively) due to the relatively high cost of medication. The costs of medication increased with increasing age of the women, irrespective of the type of treatment (IVF or ICSI). Fertilization costs (IVF laboratory) constituted 12% and 20% of the total costs of IVF and ICSI. The total cost per ICSI cycle was 8.3% higher than IVF.
Authors: M Noorashikin; F B Ong; M H Omar; M R Zainul-Rashid; A Z Murad; A Shamsir; M A Norsina; A Nurshaireen; N S M N Sharifah-Teh; A H Fazilah Journal: J Assist Reprod Genet Date: 2008-07-25 Impact factor: 3.412
Authors: E Scott Sills; Gary S Collins; Shala A Salem; Christopher A Jones; Alison C Peck; Rifaat D Salem Journal: Reprod Biol Endocrinol Date: 2012-08-30 Impact factor: 5.211
Authors: Janine G Smit; Jenneke C Kasius; Marinus J C Eijkemans; Carolien A M Koks; Ron Van Golde; Jurjen G E Oosterhuis; Annemiek W Nap; Gabrielle J Scheffer; Petra A P Manger; Annemiek Hoek; Mesrure Kaplan; Dick B C Schoot; Arne M van Heusden; Walter K H Kuchenbecker; Denise A M Perquin; Kathrin Fleischer; Eugenie M Kaaijk; Alexander Sluijmer; Jaap Friederich; Joop S E Laven; Marcel van Hooff; Leonie A Louwe; Janet Kwee; Jantien J Boomgaard; Corry H de Koning; Ineke C A H Janssen; Femke Mol; Ben W J Mol; Helen L Torrance; Frank J M Broekmans Journal: BMC Womens Health Date: 2012-08-08 Impact factor: 2.809
Authors: Theodora C van Tilborg; Marinus J C Eijkemans; Joop S E Laven; Carolien A M Koks; Jan Peter de Bruin; Gabrielle J Scheffer; Ron J T van Golde; Kathrin Fleischer; Annemieke Hoek; Annemiek W Nap; Walter K H Kuchenbecker; Petra A Manger; Egbert A Brinkhuis; Arne M van Heusden; Alexander V Sluijmer; Arie Verhoeff; Marcel H A van Hooff; Jaap Friederich; Jesper M J Smeenk; Janet Kwee; Harold R Verhoeve; Cornelis B Lambalk; Frans M Helmerhorst; Fulco van der Veen; Ben Willem J Mol; Helen L Torrance; Frank J M Broekmans Journal: BMC Womens Health Date: 2012-09-18 Impact factor: 2.809